Upadacitinib and Filgotinib: The Role of JAK1 Selective Inhibition in the Treatment of Rheumatoid Arthritis

Drugs in Context - United Kingdom
doi 10.7573/212595
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BioExcel

Related search

Upadacitinib and Filgotinib: The Role of JAK1 Selective Inhibition in the Treatment of Rheumatoid Arthritis

Drugs in Context
Molecular MedicinePharmacology
2019English

FRI0428 the JAK1-selective Inhibitor, Filgotinib, Inhibits Inflammation Pathways Observed in an IL23-induced Psoriatic Arthritis Mouse Model

2017English

Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results From Two Randomized, Controlled Phase 2b Trials

Rheumatology and Therapy
2020English

Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication

Clinical Pharmacokinetics
Pharmacology
2019English

The Treatment of Rheumatoid Arthritis.

JAMA - Journal of the American Medical Association
Medicine
1929English

Penicillamine in the Treatment of Rheumatoid Arthritis.

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
1972English

Pregnenolone in the Treatment of Rheumatoid Arthritis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
1951English

Proseptasine in the Treatment of Rheumatoid Arthritis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
1953English

The Treatment of Rheumatoid and Climacteric Arthritis

BMJ
1936English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy